Lupus

Peter Nash drpnash
1 year 3 months ago
9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024

Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Post-hoc analysis of RCTs + LTE showed Anifrolumab normalised these Haem parameters vs PBO. May improve fatigue-associated with anaemia @RheumNow https://t.co/GF8aKU0Z5x


Dr. John Cush RheumNow
1 year 3 months ago
SLE Preview: abolishing refractory with CAR-T and better B-cell therapies
Despite advancements, some SLE patients remain refractory to belimumab and off-label rituximab, the main B cell-targeted therapies in the last 15 years.
https://t.co/778buNUq1C https://t.co/4ub8VbrLb6

With a better understanding of pathophysiology, improved management guidelines, available medications, and a multidisciplinary approach, pregnancy for lupus patients has become more feasible. Despite these improvements, some patients still experience poor outcomes, highlighting the need for biomarkers that can predict these risks. An abstract presented at #EULAR2024 (POS1393) explored this possibility.

Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 Please find our Day 1 & Day 2 Recap of selective abstracts/research presented at the conference 😃@RheumNow @DrMiniDey
https://t.co/AHl18gS7gF https://t.co/LEoa9rBNly


Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ikaros) was well tolerated with
efficacy signal (SLEDAI-2K & CLASI-50). Effect and safety profile were numerically better in the lowest dose @RheumNow https://t.co/Bjk9zBRmVo


Mrinalini Dey DrMiniDey
1 year 3 months ago
🧠POS0730 Self-reported cognitive function in older adults with #SLE in @ndb_org registry
➡️Cognitive symptoms significantly worse in older people w SLE vs other #RMDs
➡️Perceptions of cognitive function assoc with less satisfaction with health & ⬇️ #QoL
@RheumNow #EULAR2024

Md Yuzaiful Md Yusof Yuz6Yusof
1 year 3 months ago
#EULAR2024 POS0529 Post-hoc analysis from Phase 2 NOBILITY showed consistent renal response was achieved in Obinutuzumab + SOC vs PBO + SOC across Complete Renal Response definitions and baseline Proteinuria levels. Assuring and looking forward to results next year @RheumNow https://t.co/wKCOP5BgoQ


Janet Pope Janetbirdope
1 year 3 months ago
#SARD #ILD
Who to screen for #rheumatic #diseases
For
ILD
#ACR guidelines
Screening May also depend on ILD prevalence
Not sure if frequency of screening and how to screen
@jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6


Bella Mehta bella_mehta
1 year 3 months ago
The original direct comparison study! https://t.co/hqrPKfNW1y


Bella Mehta bella_mehta
1 year 3 months ago
SLE RPI may be used more frequently
and can connect the digital dots! @RheumNow https://t.co/UdVIyZJhJV
